PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Zijian Leng

Chinese Academy of Medical Sciences & Peking Union Medical College

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 10, 2026 · JOURNAL ARTICLE

Efficacy and safety of sintilimab and lenvatinib combined with locoregional therapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study

Cancer Immunology Immunotherapy

A multicenter retrospective study showing improved survival and response rates with triple-combination therapy in advanced ICC, but limited by non-randomized design and moderate sample size that requires prospective confirmation.

PromisingCholangiocarcinoma and Gallbladder Cancer Studies Mingchang Pang Pengfei Hui

Reported

Median PFS (triple-regimen)11.9 months

Median PFS (ICIs-chemo)6.0 months

Median PFS (chemotherapy)5.2 months

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support